MYB and breast carcinoma: Originally, miR-193b-3p was reported to be a tumor suppressor inhibiting several tumor-associated proteins, including the MYB oncogene in T-cell acute lymphoblastic leukemia (Mets et al., 2015) and MORC4 in breast cancer (Yang et al., 2018).